Medexus Schedules Second Fiscal Quarter 2025 Conference Call
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has scheduled a conference call for November 8, 2024, at 8:00 am Eastern Time to discuss its second fiscal quarter results ending September 30, 2024. The company will release its financial statements and MD&A after market close on November 7, 2024. The call will be accessible via toll-free numbers for Canadian and U.S. callers, with international dial-in options available. A live webcast will be hosted on Medexus's corporate website, with replay access available until November 8, 2025.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) ha programmato una conferenza telefonica per l'8 novembre 2024, alle 8:00 ora orientale, per discutere i risultati del secondo trimestre fiscale chiuso il 30 settembre 2024. L'azienda pubblicherà i propri bilanci e il MD&A dopo la chiusura del mercato il 7 novembre 2024. La chiamata sarà accessibile tramite numeri verdi per i chiamanti canadesi e statunitensi, con opzioni di accesso internazionale disponibili. Sarà anche ospitata una trasmissione in diretta sul sito web aziendale di Medexus, con accesso alla registrazione disponibile fino all'8 novembre 2025.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) ha programado una llamada de conferencia para el 8 de noviembre de 2024, a las 8:00 am hora del Este, para discutir sus resultados del segundo trimestre fiscal que finalizó el 30 de septiembre de 2024. La compañía publicará sus estados financieros y el MD&A después del cierre del mercado el 7 de noviembre de 2024. La llamada será accesible a través de números gratuitos para los llamantes canadienses y estadounidenses, con opciones de marcación internacional disponibles. Se llevará a cabo una transmisión en vivo en el sitio web corporativo de Medexus, y el acceso a la repetición estará disponible hasta el 8 de noviembre de 2025.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)는 2024년 11월 8일 오전 8:00 동부 표준시(EST)에 2024 회계 연도 2분기 실적을 논의하기 위한 컨퍼런스 콜을 예정하고 있습니다. 이 회사는 2024년 11월 7일 시장 종료 후 재무제표 및 MD&A를 발표할 예정입니다. 콜은 캐나다 및 미국 전화 사용자를 위한 무료 번호를 통해 접근할 수 있으며, 국제 전화 접근 옵션도 제공됩니다. Medexus의 기업 웹사이트에서 실시간 웹캐스트가 진행되며, 재생 접근은 2025년 11월 8일까지 가능할 것입니다.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) a programmé une conférence téléphonique pour le 8 novembre 2024 à 8h00, heure de l'Est, afin de discuter de ses données du deuxième trimestre fiscal se terminant le 30 septembre 2024. L'entreprise publiera ses états financiers et son MD&A après la clôture du marché le 7 novembre 2024. L'appel sera accessible via des numéros sans frais pour les appelants canadiens et américains, avec des options d'appel international disponibles. Un webinaire en direct sera animé sur le site Web de Medexus, avec un accès à la rediffusion disponible jusqu'au 8 novembre 2025.
Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) hat eine Telefonkonferenz für den 8. November 2024 um 8:00 Uhr Eastern Time angesetzt, um die Ergebnisse des zweiten fiskalischen Quartals zum 30. September 2024 zu diskutieren. Das Unternehmen wird seine Finanzberichte und den MD&A nach Börsenschluss am 7. November 2024 veröffentlichen. Der Anruf ist über gebührenfreie Nummern für kanadische und US-Anrufer zugänglich, mit internationalen Einwahlmöglichkeiten. Ein Live-Webcast wird auf der Unternehmenswebsite von Medexus veranstaltet, mit Zugriff auf die Aufzeichnung bis zum 8. November 2025.
- None.
- None.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 29, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, November 8, 2024 to discuss Medexus's results for its second fiscal quarter ended September 30, 2024. Medexus expects to file its financial statements and MD&A after markets close on November 7, 2024.
To participate in the call, please dial the following numbers:
888-506-0062 (toll-free) for Canadian and U.S. callers
+1 973-528-0011 for international callers
Access code: 511254
A live webcast of the call will be available on the Investors section of Medexus's corporate website or at the following link:
https://www.webcaster4.com/Webcast/Page/2010/51522
A replay of the call will be available approximately one hour following the end of the call through Friday, November 15, 2024. To access the replay, please dial the following numbers –
877-481-4010 for Canadian and U.S. callers
+1 919-882-2331 for international callers
Conference ID: 51522
A replay of the webcast will be available on the Investors section of Medexus's corporate website until Saturday, November 8, 2025.
About Medexus
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.com.
Contacts
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Forward-looking statements
Certain statements made in this news release contain forward-looking information within the meaning of applicable securities laws (forward-looking statements). The words "anticipates", "believes", "expects", "will", "plans", "potential", and similar words, phrases, or expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words, phrases, or expressions. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions, and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. Medexus cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include, but are not limited to, those set out in Medexus's materials filed with the Canadian securities regulatory authorities from time to time, including Medexus's most recent annual information form and management's discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this news release. Other than as specifically required by law, Medexus undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227902
FAQ
When will Medexus Pharmaceuticals (MEDXF) release its Q2 2025 financial results?
When is Medexus Pharmaceuticals (MEDXF) Q2 2025 earnings conference call?
How long will the replay of Medexus Pharmaceuticals (MEDXF) Q2 2025 earnings call be available?
